Below are comments from Dr. Seymour on this subject, from my post of July 27, 2009. I believe this hypothesis is being tested as part of FluCide (pan-influenza) studies currently underway at Thevac, LSU.
“The scenario you suggest isn't really a vaccine. That's pre-exposure prophylaxis (PEP). A vaccine stimulates the immune system to produce an antibody IN CASE you're infected at a later date.
What you're suggesting has interested me for a long time. For example, let's say that the first case of swine flu hits a community in California. You immediately treat those initial cases (the index cases) as well as the still healthy cluster cases (those in contact with the index cases.) That way you prevent the geometric spread of the disease.
Now if in the meantime you WERE infected but FluCide knocks out the infection quickly, the trigger to stimulate the immune response was the first few hours of circulating virus. Essentially, that's a "live attenuated virus vaccine trigger" so you now have destroyed the virus with the drug and also have the immune system stimulated to produce antibodies...a double whammy in that FluCide knocks out the virus immediately but you have long term protection against that particular strain. I call it a "live attenuated virus vaccine trigger" because even though the virus may be lethal, we nail it so quickly that it can't do any damage.
This hypothesis has to be tested but it appears that it should work.
I also think that we can engineer FluCide to remain active in the body for an extended period of time so it could be used as prophylaxis in health care workers.”
AI
Market Data 
Markets 
